Drugs / recombinant Escherichia coli-asparaginase
recombinant Escherichia coli-asparaginase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00784017 | Oct 2008 → Oct 2012 | acute lymphoblastic leukemia | medac GmbH | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant Escherichia coli-asparaginase | “The efficacy and safety of recombinant Escherichia coli-asparaginase (rASNase) was compared to native E.coli asparaginase (Asparaginase medac).” PMID 29727043 ↗ May 2018 |
| Known as | rASNase | “This multicentric phase III study is designed to assess the efficacy and safety of recombinant asparaginase (rASNase) in comparison to Asparaginase medac™ during treatment of...” NCT00784017 ↗ |
| Known as | recombinant asparaginase | “This multicentric phase III study is designed to assess the efficacy and safety of recombinant asparaginase (rASNase) in comparison to Asparaginase medac™ during treatment of...” NCT00784017 ↗ |
| Known as | recombinant E. coli asparaginase | “Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch...” PMID 29727043 ↗ May 2018 |
| Route | Intravenous | “5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33” NCT00784017 ↗ |